Survey question
1: What do you think is the closest probability of eventual approval of AT for DIC in Sepsis based on review of the clinical paper “Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation”.
I would want to see a choice of zero. This paper is not sufficient for approval, IMO.
I think perhaps a better question would be to estimate chances of this and other research encouraging significant off label use of Atryn in sepsis with DIC. The reason I think this question would be helpful is that if the consensus is that off label use would be low, then GTCB/Leo would need to commit to prospective (and expensive and risky) randomized trials in sepsis with DIC if they are to ever expand use beyond hereditary deficiency.
urche
Market Data 
Markets 
AI
